BMI Department Seminar with Yeonhee Park, University of Wisconsin-Madison

The goal of phase II clinical trials is to evaluate the therapeutic efficacy of a new drug. Some use the time-to-event endpoint as the primary endpoint of the phase II study to see the improvement of the therapeutic efficacy of a new drug in median survival time. Dr. Park will discuss a method that generalizes median event time test (METT) to any percentile of the survival time using a percentile event time test (PETT), and development of data-driven monitoring for phase II clinical trials.